Innovating ADC Therapeutics Through Stable Dual Linker Payload Technology

At the forefront of our technology platform for Antibody-Drug Conjugates (ADCs) lies a suite of groundbreaking innovations. Through innovation, CBB aims to overcome the shortcomings seen with current ADCs to deliver better therapeutics for patients.

Our Unique Approach

EGCit (GluGlyCit) Enzymatically Cleavable Linker

Enhanced stability over traditional ValCit Linkers and increased hydrophilicity over traditional linkers.

Unlike conventional counterparts, this proprietary linker offers unparalleled stability against proteases, curbing premature payload release that often leads to adverse effects.

Simultaneously, it ensures swift payload release within the targeted cancer cells, maximizing the drug’s effectiveness. Moreover, its increased hydrophilicity safeguards against unintended tissue uptake, ADC aggregation, and rapid body clearance.

Read More

Enzymatic Conjugation of Branched Linkers

Relies on microbial Transglutaminase (mTG) to conjugate branched linkers to a single hlgG1 site using click chemistry, and enables rationale design of different MOA payloads.

Our pioneering technology, powered by microbial transglutaminase (mTG), enables the integration of multi-arm linkers into human IgG1 at precise locations. This results in the production of uniform ADCs with meticulous control over the Drug-to-Antibody Ratio (DAR).

Notably, this innovation allows for the development of dual-payload ADCs, promising synergistic therapeutic effects while retaining the simplicity of production akin to single-payload ADCs.

Read More

Synergistic Antibody-Payload Pairings

Through our integrated platform, we foster a diverse range of antibody-payload combinations.

By harmonizing both established and novel antibodies with various payload mechanisms of action, our technology delivers a suite of ADC products.

These products boast optimal molecular properties, pharmacological actions, and safety profiles, presenting a collection of first-in-class and best-in-class ADC solutions.

Read More

The Promise of
Our Technology

The Promise of Our Technology

Our ADC technology platform epitomizes:
Unprecedented stability against premature payload release.
Precise and targeted drug release within cancer cells.
Mitigation of off-target effects and rapid clearance.
Exact control over the Drug-to-Antibody Ratio.
Potential for synergistic therapeutic effects with dual-payload ADCs.
Fusion of diverse antibodies and payloads for optimized therapeutic outcomes.

Revolutionizing Cancer Therapeutics

With a comprehensive and versatile approach, our technology platform stands as a beacon in the realm of cancer therapeutics. It offers a promising pathway to optimize multiple critical factors, ensuring the creation of safe and effective ADCs that can revolutionize cancer treatment.

Revolutionizing Cancer Therapeutics

With a comprehensive and versatile approach, our technology platform stands as a beacon in the realm of cancer therapeutics. It offers a promising pathway to optimize multiple critical factors, ensuring the creation of safe and effective ADCs that can revolutionize cancer treatment.

Pipeline

About Us

Michael Torres, Ph.D.

Co-Founder & Chief Executive Officer

READ BIo

Abhishake Chhibber

Chief Operating Officer

READ BIo

Daniel Pereira, Ph.D.

Chief Scientific Officer

READ BIo

Morris Rosenberg, Ph.D.

Acting Chief Technology Officer

Harri Järveläinen, DVM, Ph.D., DABT, MBA

Acting Toxicologist

Scientific Advisory Board

Zhiqiang An, Ph.D.

Co-Founder & SAB

Kyoji Tsuchikama, Ph.D.

Co-Founder & SAB

READ BIo

Paolo Tarantino, M.D.

Clinical Advisor

David Hong, M.D.

Clinical Advisor

Patrick Crutcher, MSc

Board Member & Advisor

Martin Dietrich, M.D., Ph.D

Clinical Advisor

About Us

We’re insourcing from and bringing world-class scientists, operators, and drug developers to Houston, Texas with seasoned executives and consultants in key functional areas.
See Our Team

Get In Touch

Contact

Texas Medical Center Innovation
2450 Holcombe Blvd., Suite X
Houston, TX 77021

info@crossbridgebio.com

Linkedin-in

Michael Torres, Ph.D.

CO-FOUNDER & CHIEF EXECUTIVE OFFICER

Dr. Michael Jason Torres serves as the CEO of CrossBridge Bio, an innovative oncology startup spearheading the advancement of Antibody-Drug Conjugates (ADCs) to redefine cancer treatment paradigms. His entrepreneurial journey began as an Entrepreneur-In-Residence at Texas Medical Center Innovation, where he played a pivotal role in nurturing startups, facilitating their transition from ideation to operational success. Dr. Torres co-founded ReCode Therapeutics, where his leadership as a Co-Founder, Board Member, and VP of R&D propelled an academic endeavor into a robust, venture capital-backed biotech company. His strategic foresight secured a significant $3.2M Award from the CF Foundation and fostered strategic partnerships, showcasing his prowess in business development.

With a Ph.D. in cancer biology earned under the mentorship of Dr. Michael White at UT-Southwestern Medical Center, Dr. Torres boasts a robust academic foundation. His research contributions yielded numerous publications and presentations at prestigious symposia, demonstrating his commitment to advancing scientific knowledge. Furthermore, his postdoctoral research focused on decoding nonsense mutations in diseases like Cystic Fibrosis, reflecting his dedication to unraveling complex genomic illnesses. At CrossBridge Bio, Dr. Torres amalgamates his multifaceted expertise, academic excellence, and entrepreneurial spirit to lead groundbreaking research aimed at developing transformative ADCs, envisioning a future where innovative therapies alleviate the burdens of cancer and offer new avenues of hope to patients worldwide.

Abhishake Chhibber

Chief Operating Officer

Abhishake Chhibber brings over 18 years of extensive experience in the biopharmaceutical industry. This was garnered from several distinguished roles at MedImmune, AstraZeneca, and BioNTech across Finance, Strategy, Portfolio Management and Corporate Development. Notably, he played a pivotal role in building key capabilities in the strategic planning function in the Oncology Business Unit at AstraZeneca and served as the Chief Financial Officer for the Oncology Therapeutic Area at AstraZeneca.

During his tenure at BioNTech, Abhishake Chhibber focused on building the company’s strategic capabilities and driving their growth strategy. His responsibilities encompassed spearheading critical functions such as Corporate Strategy, Strategic Planning and Portfolio Management. His expertise and strategic insights have been pivotal in shaping and enhancing the company’s mid-term & long-term corporate strategy. Abhishake holds a B.S. in Biology and M.B.A from Salisbury University.

Daniel Pereira, Ph.D.

CHIEF SCIENTIFIC OFFICER

Dr. Dan Pereira brings 25 years of experience in oncology biologics drug discovery and development in biotech and pharma as a scientific leader, strategist, collaborator, consultant, and fundraiser. His career efforts have contributed to the discovery and development of a range of FDA-approved drugs for patients with cancer, including most recently Padcev. Before joining Crossbridge Bio as Acting CSO, Dan was Chief Scientific Officer for Invenra, leading efforts to advance novel bispecific antibodies into clinical trials for oncology. Preceding Invenra, Dan was CSO for Arch Oncology, heading a team focused on next generation I-O therapeutics including AO-176, a differentiated CD47 antibody. Prior to Arch Oncology, Dan was Vice President, Head of Discovery Research at Agensys Inc., a subsidiary of Astellas Pharma, Inc. where he oversaw research efforts to develop novel antibody based I-O therapies including antibody-drug conjugates and bispecific antibodies. Dan also served as VP, Research and site head at Roche/Arius and Director of Tumor Biology at ImClone Systems Inc. Dr. Pereira received bachelor’s and master’s degrees from the University of Manitoba and holds a doctoral degree from McMaster University. He has an extensive record of both peer-reviewed publications and conference presentations and is a named inventor on numerous patents.

Kyoji Tsuchikama, Ph.D.

Co-Founder & SAB

Kyoji brings a wealth of expertise and skills in organic chemistry, chemical biology, and medicinal chemistry, pivotal for successful project execution. With a career spanning diverse domains, he has honed skills in organic synthesis, proteomic analysis, chemical protein engineering, and preclinical drug development. His journey started with graduate studies in organic chemistry, followed by postdoctoral work bridging chemistry and biology to unravel biomolecular mechanisms in bacterial physiology and identify therapeutic targets using chemical probe-based proteomic profiling.

Since 2014, as a Principal Investigator at UTHealth Houston, Kyoji has led groundbreaking medicinal chemistry projects focused on pioneering novel antibody-drug conjugates (ADCs). These initiatives have received substantial support from prestigious bodies like NIH/NCI R01, NIH/NIGMS R35, and DOD, underscoring the impact and quality of our research. Additionally, his role as Co-Investigator overseeing ADC production in the CPRIT-funded Cancer Antibody Drug Modalities Core Facility underscores his commitment to advancing therapeutic innovation.

Kyoji’s contributions have been recognized globally, evident through accolades like the 2021 Outstanding Academic Investigator Award from the World ADC San Diego, a testament to our lab’s forefront position in ADC research. Notably, his research, published in esteemed journals, has garnered acclaim, including the Best Preclinical Publication Award from the World ADC San Diego for our pioneering work on dual-drug ADCs. Training the next generation of researchers is also a priority, having mentored seven postdocs, two of whom secured the prestigious fellowship provided by the Japan Society for the Promotion of Science.